11083results about "Extracellular fluid disorder" patented technology

Disclosed in the present invention are a polycyclic derivative, and a preparation method therefor and the use thereof. In particular, the present invention relates to a compound represented by general formula (I) or a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition comprising the compound, and the use thereof in the preparation of a drug for treating diseases. The compound has a structure as represented by formula (I).

The invention provides a plant lactobacillus capable of promoting mineral absorption and transport and application of the plant lactobacillus. The invention provides a plant lactobacillus of which the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.32404. The invention also provides a culture, a sterilized solution, a supernatant, a filtrate, a diluent, a precipitate or freeze-dried powder, a composition and a probiotic preparation containing the plant lactobacillus, and related applications and methods thereof.

The invention provides an artificial nucleic acid molecule which is used for improving the expression quantity of target amino acid, polypeptide or protein. The artificial nucleic acid molecule at least comprises a target 5'untranslated region (UTR), a target coding region (CDS) and a target 3 'untranslated region (UTR). Wherein the sequence of the target 5 'UTR is one of the following sequences: 5' UTR of a high-expression gene and a 5 'UTR variant of the high-expression gene. The sequence of the target 3 'UTR is one of the following sequences: 3' UTR of a high-expression gene and a 3 'UTR variant of the high-expression gene. Optionally, the artificial nucleic acid molecule may further comprise, for example, a 5 '-end cap structure (Cap), a PolyA tail. The 5 'UTR and the 3' UTR have regulating effects on translation and stability of nucleic acid molecules, so that the 5 'UTR, the 3' UTR and variants thereof are selected from high-expression genes, the nucleic acid molecules can be further stabilized and are not easy to degrade, and the amount of protein or polypeptide obtained by translation of the nucleic acid molecules can be increased. The invention also provides methods for making, delivering, and using such artificial nucleic acid molecules, as well as the use of the artificial nucleic acid molecules for the treatment and / or prevention of related diseases or disorders.

A synergistic composition for improving the bioaccessibility of minerals comprises lutein, a casein phosphopeptide, or a 1, 3-dioleoyl-2-palmitic acid triglyceride, preferably in combination with one or more non-digestible oligosaccharides. These compositions are useful for the prevention and / or treatment of mineral deficiency and related conditions, preferably anemia, said minerals comprising iron and / or calcium.

Provided herein are lipids having the Formula I or Formula Ia:and pharmaceutically acceptable salts thereof, wherein R′, R1, R2, R3, R4, R5, R6a, R6b, X1, X2, and n are as defined herein for Formula I and Formula Ia, respectively. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula I or Ia and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).

The invention belongs to the technical field of biomedical materials, and relates to ultrasonic response adhesion integrated hydrogel as well as a preparation method and application thereof, the hydrogel comprises a hydrogel matrix, an interface anchoring agent and a functional load component; the preparation method comprises the following steps: 1, preparing a hydrogel precursor solution, and preparing a hydrogel matrix into a solution; 2, carrying out mold molding or injection crosslinking on the solution prepared in the step 1 to form hydrogel; 3, preparing an interface anchoring agent solution, and dissolving or dispersing an interface anchoring agent in a solvent to prepare the interface anchoring agent solution; the ultrasonic responsive adhesive hydrogel platform provided by the invention can provide an efficient, controllable and universal solution for tissue adhesion, targeted therapy, wearable attachment and the like in a complex microenvironment, and is suitable for a plurality of clinical scenes such as chronic wound management, surgical postoperative closure, infection control, adhesive bioelectronic fixation, soft tissue engineering and the like.

The present application relates to animal bifidobacterium lactis Ca360 and its application. The present application also provides the application of animal bifidobacterium lactis in promoting the absorption and transport of minerals, improving osteoporosis, iron deficiency anemia and zinc deficiency. The animal bifidobacterium lactis of the present application can promote the absorption and transport of minerals, improve osteoporosis, iron deficiency anemia and zinc deficiency.

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

The invention provides cat serum albumin and application thereof, and relates to the technical field of protein engineering. According to the invention, mutation is carried out on the cat serum albumin for the first time to obtain a beneficial mutation site, so that the cat serum albumin mutant which can be highly expressed in a pichia pastoris system is obtained. In addition, the cat serum albumin mutant I31L also has the effect of treating ascites due to cirrhosis, and the treatment effect is obviously higher than that in the prior art. A new biological material is provided for application of the cat serum albumin, and a foundation is laid for genetic engineering modification of the cat serum albumin.

The invention discloses an oral care desensitization paste and a preparation method thereof, and mainly relates to the technical field of dental medicines. The oral care desensitization cream is prepared from the following components: bioactive glass, strontium chloride, sodium chloride, silicon dioxide, sodium carboxymethyl cellulose, polyethylene glycol 400, a xanthan gum solution, sodium lauryl sulfate, sodium lauroyl sarcosinate, titanium dioxide, beta-glucan, saccharin sodium salt, sorbitol, methylparaben, propyl hydroxybenzoate, edible essence and water. Compared with the prior art, the oral care desensitization paste disclosed by the invention can be used for sealing dentinal tubules and treating hemodia; the traditional Chinese medicine composition can also be used for treating plaque gingivitis, relieving and reducing gingival bleeding and inhibiting and reducing dental plaque; and meanwhile, the condition of mistakenly swallowing and eating in the using process is reduced.

The invention relates to the technical field of traditional Chinese medicine, in particular to a Mongolian medicine tea drink for relieving respiratory system abnormality and a preparation method and application thereof.The Mongolian medicine tea drink is prepared from rhododendron micranthum, pomegranate, amomum cardamomum, long pepper, cinnamon, safflower, agilawood, clove, myristica fragrans, fructus choerospondiatis, bistort rhizome, liquorice, tabasheer, radix aucklandiae, white raisin and crabs. The processed products of the Mongolian medicine components are weighed according to the formula dosage, then ground into coarse powder and bagged to prepare tea bags. The Mongolian medicine tea drink provided by the invention has the effects of moving Heli, relieving cough, reducing phlegm and diminishing swelling; the traditional Chinese medicine composition can be used for treating the symptoms such as' Bada dry Hiri 'dizziness, asthma, chronic bronchitis, indigestion disease, edema, edema and water tympanites.

The present invention relates to ultrasound (US) mediated delivery of therapeutic agents, such as the delivery of a drug, gene, nanoparticle or radioisotope, using a bi-phasic microparticle system comprising gas microbubbles, emulsion microdroplets and clusters thereof. Thus, the present invention relates to a cluster composition and a pharmaceutical composition, and their use for delivery of therapeutic agents and as a contrast agent for ultrasound imaging. It further relates to methods for delivering such therapeutic agents and to the use of said compositions.

The invention relates to bifidobacterium animalis subsp. Lactis Ca360 and application thereof. The invention further provides application of the animal bifidobacterium subsp. Lactis in promoting absorption and transport of mineral substances and improving osteoporosis, iron-deficiency anemia and zinc deficiency. The bifidobacterium animalis subsp. Lactis disclosed by the invention can promote absorption and transport of mineral substances and improve osteoporosis, iron-deficiency anemia and zinc deficiency.

The invention features polypeptides that include an extracellular ActRIIA variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIA variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving low red blood cell levels, e.g., anemia or blood loss; fibrosis; or pulmonary hypertension.

The invention provides a combined fermented product of ginseng, astragalus membranaceus and donkey-hide gelatin as well as a preparation method and application of the combined fermented product, and relates to the technical field of pharmaceutical preparations. The combined leavening is obtained by fermenting ginseng, astragalus membranaceus and donkey-hide gelatin, and the mass ratio of the ginseng to the astragalus membranaceus to the donkey-hide gelatin is (1-3): (10-30): 1. The composition of ginseng, astragalus membranaceus and colla corii asini is subjected to probiotic fermentation, macromolecular saponin is converted into aglycone or secondary saponin with smaller molecules, protein is split into peptide chains with smaller molecules, polysaccharide is split into sugar chains with smaller molecules, absorption and utilization of effective components of the medicine are facilitated, and the effect of tonifying qi and blood can be rapidly achieved.

The invention belongs to the technical field of microorganisms, and provides streptococcus salivarius subsp. Thermophilus HX-ST36, and the preservation number of the streptococcus salivarius subsp. Thermophilus HX-ST36 is CGMCC NO.32955. The streptococcus salivarius subsp. Thermophilus provided by the invention can be used for fermenting astragalus membranaceus-angelica sinensis. In a cold coagulation and blood stasis type primary dysmenorrheal model mouse, a fermentation product can remarkably inhibit the writhing reaction, and the effects of relieving dysmenorrheal and enriching blood can be achieved by reducing the levels of prostaglandin PGF2 and vasopressin ADH in uterine tissue and increasing the content of hemoglobin (HGB). The dampness clearing effect of the fermentation product is verified by improving the heavy physical sign of moisture through crowd experiments. The invention also provides a preparation method of the probiotic preparation and the probiotic fermentation product. The preparation methods of the probiotic preparation and the probiotic fermentation product are simple, and large-scale production can be realized.

Aspects of the disclosure provides composition and methods for treating a subject having a blood loss condition, the method comprising administering to the subject a hemojuvelin (HIV) antagonist (e.g., anti-HJV antibody).

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

The present invention relates to a nucleic acid molecule inhibiting factor 11 (FXI) gene expression in a cell by means of RNAi, comprising a sense sequence and an antisense sequence complementary to each other, or consisting of a sense sequence and an antisense sequence complementary to each other. The FXI inhibition rate of the nucleic acid molecule is significantly superior to that of other small nucleic acid molecules which inhibit the expression of FXI by means of RNAi.

The invention discloses a traditional Chinese medicine composition with the effects of benefiting qi, nourishing blood, invigorating the spleen and tonifying the kidney and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: cistanche, ginseng, American ginseng, astragalus membranaceus, medlar, rhizoma polygonati, oyster peptide, angelica sinensis, radix rehmanniae preparata, donkey-hide gelatin, fructus amomi, pericarpium citri reticulatae, hawthorn, folium cortex eucommiae, radix puerariae, liquorice and the like. The preparation method comprises the following steps: respectively crushing the medicinal materials, dissolving the colla corii asini, mixing, adding water, granulating and the like. The composition can be prepared into various dosage forms such as granules, capsules, tablets, oral liquid and the like. Experiments show that the traditional Chinese medicine composition can effectively improve the symptoms of deficiency of qi and blood (increasing erythrocyte count and hemoglobin content), weakness of spleen and stomach (increasing body weight and improving pepsin activity) and kidney deficiency (reducing creatinine and urea nitrogen content and improving SOD activity), and acute toxicity experiments show that the toxicity is slightly reversible under high dosage, and the safety is good under therapeutic dosage. The traditional Chinese medicine composition has potential application value in the aspect of preparing medicines for benefiting qi, nourishing blood, invigorating spleen and tonifying kidney.

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of Cas9 and nucleic acid editing proteins or protein domains, e.g., deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of Cas9 and nucleic acid editing proteins or domains, are provided.

Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and / or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

The embodiment of the invention discloses human-derived recombinant III-type collagen as well as a preparation method and application thereof. The amino acid sequence of the human-derived recombinant III-type collagen comprises a basic repetitive unit, and the amino acid sequence of the basic repetitive unit is as shown in SEQ ID NO.4. The amino acid sequence of the basic repetitive unit is as shown in SEQ ID NO.3. The amino acid sequence of the basic repetitive unit is as shown in SEQ ID NO.4. The amino acid sequence of the human recombinant III type collagen is shown as SEQ ID NO.3. The invention also discloses a preparation method of the human recombinant III type collagen. According to the invention, a human recombinant III-type collagen gene with the coding molecular weight of 60kD is designed, an escherichia coli expression strain is constructed and expressed, the yield of the human recombinant III-type collagen is increased through amplification culture on a fermentation tank, and the protein purity is improved by virtue of strategies such as ultrafiltration primary purification and affinity chromatography. The human-derived recombinant III-type collagen prepared by the invention avoids potential hidden dangers such as animal diseases or viruses and immunological rejection caused by a traditional extraction method, has excellent medical performance, can effectively control the production cost and the product quality by virtue of a fermentation preparation process, and is also easy to realize large-scale production.

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

The invention provides a compound of a GLP-1R agonist or modulator with a structure as shown in a formula (I).

Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and / or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.

The invention discloses an indobufen sustained release preparation as well as a preparation method and application thereof. The sustained-release preparation comprises a main drug, a sustained-release material, a filler and an adhesive, and realizes the slow release of the drug, the number of times of taking the drug by a patient is reduced, the risk of missing taking is reduced, and the medication compliance of the patient is improved; active ingredients can be continuously and stably released, the peak blood concentration of the medicine is reduced, and the stimulation to gastrointestinal tracts is reduced. The preparation method is simple and easy to control, low in cost, good in process reproducibility and suitable for industrial mass production.